AbSci fetches $12 mln Series C
Vancouver, Washington-based AbSci, a provider of biomanufacturing technologies, has closed $12 million in Series C financing. Asahi Glass Co. Ltd led the round with participation from Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, Souther Co., Columbia Ventures Corporation and GreenBridge. In conjunction with the funding, Dr. Gustavo Mahler, president and CEO of AGC Biologics, will join AbSci's board of directors.
30 May 2018•1 min read
